New heart attack treatment aims to slash cholesterol, prevent repeat events
NCT ID NCT04951856
Summary
This study is testing if adding a cholesterol-lowering injection called evolocumab to standard care is better at reaching very low cholesterol goals after a heart attack. It involves over 2,100 patients in Europe who have had a serious heart attack and received a stent. The main goal is to see if this approach is more effective than standard medications alone at controlling 'bad' cholesterol one year later to help prevent another heart attack.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSTEMI - NON-ST SEGMENT ELEVATION MI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.